NASDAQ:NBIX Neurocrine Biosciences (NBIX) Stock Price, News & Analysis → SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad) Free NBIX Stock Alerts $135.41 -1.25 (-0.91%) (As of 05/31/2024 08:51 PM ET) Add Compare Share Share Today's Range$133.57▼$137.2750-Day Range$131.74▼$143.1952-Week Range$89.04▼$148.37Volume1.54 million shsAverage Volume831,869 shsMarket Capitalization$13.63 billionP/E Ratio37.30Dividend YieldN/APrice Target$150.85 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Neurocrine Biosciences alerts: Email Address Neurocrine Biosciences MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.80 Rating ScoreUpside/Downside11.4% Upside$150.85 Price TargetShort InterestHealthy1.85% of Shares Sold ShortDividend StrengthN/ASustainability-2.61Upright™ Environmental ScoreNews Sentiment0.58Based on 23 Articles This WeekInsider TradingSelling Shares$29.26 M Sold Last QuarterProj. Earnings Growth59.43%From $4.19 to $6.68 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.72 out of 5 starsMedical Sector56th out of 924 stocksBiological Products, Except Diagnostic Industry5th out of 151 stocks 3.4 Analyst's Opinion Consensus RatingNeurocrine Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 18 buy ratings, 6 hold ratings, and no sell ratings.Amount of Analyst CoverageNeurocrine Biosciences has been the subject of 14 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Neurocrine Biosciences' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted1.85% of the outstanding shares of Neurocrine Biosciences have been sold short.Short Interest Ratio / Days to CoverNeurocrine Biosciences has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Neurocrine Biosciences has recently increased by 1.64%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldNeurocrine Biosciences does not currently pay a dividend.Dividend GrowthNeurocrine Biosciences does not have a long track record of dividend growth. Previous Next 2.9 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreNeurocrine Biosciences has received a 24.32% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Valbenazine", "Elagolix", and "Opicapone" products. See details.Environmental SustainabilityThe Environmental Impact score for Neurocrine Biosciences is -2.61. Previous Next 2.5 News and Social Media Coverage News SentimentNeurocrine Biosciences has a news sentiment score of 0.58. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.77 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 23 news articles for Neurocrine Biosciences this week, compared to 9 articles on an average week.Search InterestOnly 3 people have searched for NBIX on MarketBeat in the last 30 days. This is a decrease of -40% compared to the previous 30 days.MarketBeat Follows11 people have added Neurocrine Biosciences to their MarketBeat watchlist in the last 30 days. This is an increase of 120% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Neurocrine Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $29,263,354.00 in company stock.Percentage Held by InsidersOnly 4.30% of the stock of Neurocrine Biosciences is held by insiders.Percentage Held by Institutions92.59% of the stock of Neurocrine Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Neurocrine Biosciences' insider trading history. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for Neurocrine Biosciences are expected to grow by 59.43% in the coming year, from $4.19 to $6.68 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Neurocrine Biosciences is 37.30, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 130.53.Price to Earnings Ratio vs. SectorThe P/E ratio of Neurocrine Biosciences is 37.30, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 122.22.Price to Book Value per Share RatioNeurocrine Biosciences has a P/B Ratio of 5.96. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Neurocrine Biosciences' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Priority GoldAlert: Your Bank is Dying – Act Now or Lose Everything!Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.Click here for your free guide About Neurocrine Biosciences Stock (NASDAQ:NBIX)Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy in pediatrics and adults; NBI-921352 to treat developmental and epileptic encephalopathy syndrome in pediatrics and adults; NBI-827104 to treat epileptic encephalopathy with continuous spike-and-wave during sleep; NBI-1076986 to treat movement disorders; crinecerfront to treat congenital adrenal hyperplasia in adults and children; EFMODY to treat congenital adrenal hyperplasia and adrenal insufficiency in adults; valbenazine for the adjunctive treatment of schizophrenia; NBI-1065845 for the treatment of inadequate response to treatment in major depressive disorder; luvadaxistat to treat cognitive impairment related to schizophrenia; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; NBI-1117570 for the treatment of symptoms of psychosis and cognition in neurological and neuropsychiatric conditions; and NBI-1117569, NBI-1117567, and NBI-1065890 to treat CNS indications. The company also has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.Read More NBIX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NBIX Stock News HeadlinesMay 31 at 8:42 AM | insidertrades.comNeurocrine Biosciences, Inc. (NASDAQ:NBIX) Director Sells $5,338,400.00 in StockMay 22, 2024 | insidertrades.comNeurocrine Biosciences, Inc. (NASDAQ:NBIX) Director Shalini Sharp Sells 1,106 SharesMay 17, 2024 | insidertrades.comInsider Selling: Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Director Sells 12,500 Shares of StockMay 9, 2024 | insidertrades.comInsider Selling: Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Insider Sells 273 Shares of StockJune 3 at 8:01 AM | prnewswire.comNeurocrine Biosciences Presented CAHtalyst™ Phase 3 Pediatric and Adult Studies, CAHtalog™ Registry and Disease- and Glucocorticoid-Related Comorbidities Data in CAH at ENDO 2024June 3 at 7:35 AM | prnewswire.comNeurocrine Biosciences Announces Publication of Primary CAHtalyst™ Pediatric Phase 3 Study Results of Crinecerfont for the Treatment of CAH in The New England Journal of MedicineJune 3 at 7:30 AM | prnewswire.comNeurocrine Biosciences Announces Publication of Primary CAHtalyst™ Adult Phase 3 Study Results of Crinecerfont for the Treatment of CAH in The New England Journal of MedicineJune 2 at 4:16 AM | americanbankingnews.comInsider Selling: Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Director Sells 40,000 Shares of StockMay 31 at 8:32 AM | americanbankingnews.comNeurocrine Biosciences (NASDAQ:NBIX) Trading Down 5.3%May 31 at 4:02 AM | americanbankingnews.comNeurocrine Biosciences (NASDAQ:NBIX) Stock Rating Reaffirmed by WedbushMay 29, 2024 | markets.businessinsider.comOppenheimer Reaffirms Their Buy Rating on Neurocrine (NBIX)May 29, 2024 | prnewswire.comNeurocrine Biosciences to Participate at Investor Conferences in JuneMay 29, 2024 | americanbankingnews.comNeurocrine Biosciences (NASDAQ:NBIX) Price Target Increased to $193.00 by Analysts at UBS GroupMay 29, 2024 | markets.businessinsider.comNeurocrine Biosciences CEO Kevin Gorman To Retire; Appoints Kyle Gano As CEO-electMay 28, 2024 | marketwatch.comNeurocrine Biosciences Names Kyle Gano as Next CEOMay 28, 2024 | reuters.comNeurocrine founder-CEO Gorman to retire in OctoberMay 28, 2024 | prnewswire.comNeurocrine Biosciences Announces CEO Succession PlanMay 28, 2024 | markets.businessinsider.comKey Takeaways From Neurocrine Biosciences Analyst RatingsMay 28, 2024 | prnewswire.comNeurocrine Biosciences to Present New Phase 3 CAHtalyst™ Data in Adult and Pediatric Patients with CAH and Study Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH at ENDO 2024May 21, 2024 | prnewswire.comNeurocrine Biosciences Announces Publication of Phase 3 KINECT®-4 Post Hoc Analysis Demonstrating Clinically Meaningful and Sustained Improvement in Tardive Dyskinesia With Long-Term Use of INGREZZA® (valbenazine) CapsulesMay 14, 2024 | nasdaq.comEvercore ISI Group Initiates Coverage of Neurocrine Biosciences (NBIX) with Outperform RecommendationMay 14, 2024 | prnewswire.comNeurocrine Biosciences Presented Baseline Data from the CAHtalyst™ Program in CAH and Study Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH at ECE 2024May 9, 2024 | finance.yahoo.comHow Neurocrine Is Stacking Up Wins In 2024 — And Outperforming PeersMay 9, 2024 | finance.yahoo.comHow Neurocrine, An IBD 50 Stock, Is Stacking Up Wins In 2024 — And Outperforming PeersMay 9, 2024 | prnewswire.comNeurocrine Biosciences Presents CAHtalyst™ Adult Study Baseline Characteristics and Data on Impact of Supraphysiologic Glucocorticoid Therapy at AACE 2024See More Headlines Receive NBIX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Neurocrine Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/01/2024Today6/03/2024Next Earnings (Estimated)8/06/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryBiotechnology Current SymbolNASDAQ:NBIX CUSIP64125C10 CIK914475 Webwww.neurocrine.com Phone(858) 617-7600Fax858-617-7602Employees1,400Year FoundedN/APrice Target and Rating Average Stock Price Target$150.85 High Stock Price Target$216.00 Low Stock Price Target$100.00 Potential Upside/Downside+11.4%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage25 Analysts Profitability EPS (Most Recent Fiscal Year)$3.63 Trailing P/E Ratio37.30 Forward P/E Ratio32.32 P/E GrowthN/ANet Income$249.70 million Net Margins18.65% Pretax Margin23.71% Return on Equity17.45% Return on Assets12.14% Debt Debt-to-Equity RatioN/A Current Ratio2.52 Quick Ratio2.47 Sales & Book Value Annual Sales$1.89 billion Price / Sales7.22 Cash Flow$2.58 per share Price / Cash Flow52.50 Book Value$23.71 per share Price / Book5.71Miscellaneous Outstanding Shares100,640,000Free Float96,310,000Market Cap$13.63 billion OptionableOptionable Beta0.28 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesDr. Kevin C. Gorman Ph.D. (Age 66)CEO & Director Comp: $2.05MMr. Matthew C. Abernethy (Age 44)Chief Financial Officer Comp: $1.06MDr. Jude Onyia Ph.D. (Age 60)Chief Scientific Officer Comp: $1.22MMr. Kyle W. Gano Ph.D. (Age 51)Chief Business Development & Strategy Officer Comp: $990.12kDr. Eiry Wyn Roberts M.D. (Age 60)Chief Medical Officer Comp: $1.12MJane SorensenHead of Investor RelationsMr. Darin M. Lippoldt Esq. (Age 58)Chief Legal Officer & Corporate Secretary Comp: $921.01kMs. Julie S. Cooke (Age 58)Chief Human Resources Officer Mr. Eric S. Benevich (Age 59)Chief Commercial Officer Comp: $805kMr. David Warren Boyer (Age 44)Chief Corporate Affairs Officer More ExecutivesKey CompetitorsBio-TechneNASDAQ:TECHAcceleron PharmaNASDAQ:XLRNQiagenNYSE:QGENMomenta PharmaceuticalsNASDAQ:MNTACRISPR TherapeuticsNASDAQ:CRSPView All CompetitorsInsiders & InstitutionsStephen A SherwinSold 40,000 sharesTotal: $5.34 M ($133.46/share)Burney Co.Sold 8,895 shares on 5/22/2024Ownership: 0.079%Swedbank ABBought 14,012 shares on 5/21/2024Ownership: 0.014%Virtu Financial LLCBought 4,212 shares on 5/20/2024Ownership: 0.004%Motley Fool Asset Management LLCBought 197 shares on 5/17/2024Ownership: 0.002%View All Insider TransactionsView All Institutional Transactions NBIX Stock Analysis - Frequently Asked Questions Should I buy or sell Neurocrine Biosciences stock right now? 25 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Neurocrine Biosciences in the last twelve months. There are currently 6 hold ratings, 18 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" NBIX shares. View NBIX analyst ratings or view top-rated stocks. What is Neurocrine Biosciences' stock price target for 2024? 25 brokers have issued 1 year target prices for Neurocrine Biosciences' stock. Their NBIX share price targets range from $100.00 to $216.00. On average, they predict the company's stock price to reach $150.85 in the next twelve months. This suggests a possible upside of 11.4% from the stock's current price. View analysts price targets for NBIX or view top-rated stocks among Wall Street analysts. How have NBIX shares performed in 2024? Neurocrine Biosciences' stock was trading at $131.76 at the beginning of the year. Since then, NBIX stock has increased by 2.8% and is now trading at $135.41. View the best growth stocks for 2024 here. When is Neurocrine Biosciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 6th 2024. View our NBIX earnings forecast. How were Neurocrine Biosciences' earnings last quarter? Neurocrine Biosciences, Inc. (NASDAQ:NBIX) announced its quarterly earnings data on Wednesday, May, 1st. The company reported $0.42 earnings per share for the quarter, missing the consensus estimate of $1.04 by $0.62. The firm had revenue of $515.30 million for the quarter, compared to the consensus estimate of $512.21 million. Neurocrine Biosciences had a trailing twelve-month return on equity of 17.45% and a net margin of 18.65%. What ETFs hold Neurocrine Biosciences' stock? ETFs with the largest weight of Neurocrine Biosciences (NASDAQ:NBIX) stock in their portfolio include Invesco Biotechnology & Genome ETF (PBE), iShares Neuroscience and Healthcare ETF (IBRN), First Trust NYSE Arca Biotechnology Index Fund (FBT), Janus Henderson Small/Mid Cap Growth Alpha ETF (JSMD), Goldman Sachs Future Health Care Equity ETF (GDOC), VanEck Biotech ETF (BBH), Simplify Health Care ETF (PINK) and Virtus LifeSci Biotech Products ETF (BBP). What is Kevin C. Gorman's approval rating as Neurocrine Biosciences' CEO? 11 employees have rated Neurocrine Biosciences Chief Executive Officer Kevin C. Gorman on Glassdoor.com. Kevin C. Gorman has an approval rating of 97% among the company's employees. This puts Kevin C. Gorman in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Neurocrine Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Neurocrine Biosciences investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Micron Technology (MU), Alibaba Group (BABA), Netflix (NFLX), AbbVie (ABBV), Walt Disney (DIS), Tesla (TSLA), Block (SQ) and Salesforce (CRM). Who are Neurocrine Biosciences' major shareholders? Neurocrine Biosciences' stock is owned by a number of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (9.87%), Bellevue Group AG (2.04%), Janus Henderson Group PLC (1.37%), Bank of New York Mellon Corp (0.93%), Jacobs Levy Equity Management Inc. (0.71%) and Allspring Global Investments Holdings LLC (0.51%). Insiders that own company stock include Darin Lippoldt, David W Boyer, Dimitri E Grigoriadis, Eiry Roberts, Eric Benevich, Gary A Lyons, George J Morrow, Ingrid Delaet, Jude Onyia, Julie Cooke, Kevin Charles Gorman, Kyle Gano, Leslie V Norwalk, Malcolm Lloyd-Smith, Matt Abernethy, Neurocrine Biosciences Inc, Richard F Pops, Shalini Sharp, Stephen A Sherwin and William H Rastetter. View institutional ownership trends. How do I buy shares of Neurocrine Biosciences? Shares of NBIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:NBIX) was last updated on 6/3/2024 by MarketBeat.com Staff From Our PartnersWrite this ticker symbol down…StocksToTradeTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProMust-See: Elon’s New Invention is Absolutely InsaneInvestorPlaceExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersHe Is Giving Away BitcoinCrypto Swap ProfitsShocking $16T Elon Musk Crypto LeakCrypto 101 MediaBiden replacement revealed?Paradigm PressBiden Nomination CANCELED?The Freeport Society Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neurocrine Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.